Neuromotor and cognitive outcomes of early treatment in tyrosine hydroxylase deficiency type B

Neurology. 2017 Jan 31;88(5):501-502. doi: 10.1212/WNL.0000000000003539. Epub 2016 Dec 30.

Authors

Vincenzo Leuzzi¹, Mario Mastrangelo², Maria Teresa Giannini², Riccardo Carbonetti², Georg F Hoffmann²

Affiliations

¹ From the La Sapienza University of Rome (V.L., M.M., M.T.G., R.C.), Italy; and University of Heidelberg (G.F.H.), Germany. [email protected].
² From the La Sapienza University of Rome (V.L., M.M., M.T.G., R.C.), Italy; and University of Heidelberg (G.F.H.), Germany.

PMID: 28039315
DOI: 10.1212/WNL.0000000000003539

No abstract available

Publication types

Case Reports

MeSH terms

Adolescent
Cognitive Dysfunction / diagnosis
Cognitive Dysfunction / drug therapy*
Cognitive Dysfunction / etiology
Dopamine Agents / therapeutic use*
Dystonic Disorders / complications
Dystonic Disorders / congenital*
Dystonic Disorders / diagnosis
Dystonic Disorders / drug therapy
Early Diagnosis
Humans
Levodopa / therapeutic use
Male
Motor Skills Disorders / diagnosis
Motor Skills Disorders / drug therapy*
Motor Skills Disorders / etiology
Treatment Outcome

Substances

Dopamine Agents
Levodopa

Supplementary concepts

Segawa syndrome, autosomal recessive